Company registration number 14628519 (England and Wales)
BAINBRIDGE BIO LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2026
PAGES FOR FILING WITH REGISTRAR
BAINBRIDGE BIO LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 6
BAINBRIDGE BIO LTD
BALANCE SHEET
AS AT
31 JANUARY 2026
31 January 2026
- 1 -
2026
2025
Notes
£
£
£
£
Fixed assets
Intangible assets
5
11,157
5,800
Tangible assets
6
518
983
11,675
6,783
Current assets
Debtors
7
86,549
82,849
Cash at bank and in hand
19,351
22,252
105,900
105,101
Creditors: amounts falling due within one year
8
(527,911)
(396,202)
Net current liabilities
(422,011)
(291,101)
Net liabilities
(410,336)
(284,318)
Capital and reserves
Called up share capital
9
1
1
Profit and loss reserves
(410,337)
(284,319)
Total equity
(410,336)
(284,318)

For the financial year ended 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 29 May 2026 and are signed on its behalf by:
Dr S Bidinger
Director
Company registration number 14628519 (England and Wales)
BAINBRIDGE BIO LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2026
- 2 -
1
Accounting policies
Company information

Bainbridge Bio Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 34 High Street, Aldridge, Walsall, West Midlands, WS9 8LZ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

A true t the time of approving the financial statements, t he directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus t he directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred.

1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Patents & licences
15 years straight line
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computers
3 years straight line
1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in bank only.

BAINBRIDGE BIO LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
1
Accounting policies
(Continued)
- 3 -
1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include corporation tax recoverable, other debtors, and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including trade creditors, amounts owed to group undertakings, taxation and social security, and other creditors, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs.

BAINBRIDGE BIO LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
1
Accounting policies
(Continued)
- 4 -
1.10
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.11
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense.

1.12
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.13
Government grants

Government grants are recognised at the fair value of the asset receive d or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2026
2025
Number
Number
Total
2
2
BAINBRIDGE BIO LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
- 5 -
4
Taxation
2026
2025
£
£
Current tax
UK corporation tax on profits for the current period
(58,192)
(41,964)
Adjustments in respect of prior periods
-
0
(27,266)
Total current tax
(58,192)
(69,230)
5
Intangible fixed assets
Patents & licences
£
Cost
At 1 February 2025
5,800
Additions
5,939
At 31 January 2026
11,739
Amortisation and impairment
At 1 February 2025
-
0
Amortisation charged for the year
582
At 31 January 2026
582
Carrying amount
At 31 January 2026
11,157
At 31 January 2025
5,800
6
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 February 2025 and 31 January 2026
1,396
Depreciation and impairment
At 1 February 2025
413
Depreciation charged in the year
465
At 31 January 2026
878
Carrying amount
At 31 January 2026
518
At 31 January 2025
983
BAINBRIDGE BIO LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
- 6 -
7
Debtors
2026
2025
Amounts falling due within one year:
£
£
Corporation tax recoverable
58,192
69,381
Other debtors
28,357
13,468
86,549
82,849
8
Creditors: amounts falling due within one year
2026
2025
£
£
Trade creditors
560
30
Amounts owed to group undertakings
514,952
384,117
Taxation and social security
5,189
7,054
Other creditors
7,210
5,001
527,911
396,202
9
Called up share capital
2026
2025
2026
2025
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
1
1
1
1
10
Related party transactions

Included within creditors falling due within one year is a balance of £514,952 (202 5: £384,117) owed to group undertakings. This loan is interest free and repayable on demand.

2026-01-31 2025-02-01 false false false 29 May 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mr D Bidinger S Bidinger Mr J F McAleer 14628519 2025-02-01 2026-01-31 14628519 2026-01-31 14628519 2025-01-31 14628519 core:PatentsTrademarksLicencesConcessionsSimilar 2026-01-31 14628519 core:PatentsTrademarksLicencesConcessionsSimilar 2025-01-31 14628519 core:OtherPropertyPlantEquipment 2026-01-31 14628519 core:OtherPropertyPlantEquipment 2025-01-31 14628519 core:CurrentFinancialInstruments core:WithinOneYear 2026-01-31 14628519 core:CurrentFinancialInstruments core:WithinOneYear 2025-01-31 14628519 core:CurrentFinancialInstruments 2026-01-31 14628519 core:CurrentFinancialInstruments 2025-01-31 14628519 core:ShareCapital 2026-01-31 14628519 core:ShareCapital 2025-01-31 14628519 core:RetainedEarningsAccumulatedLosses 2026-01-31 14628519 core:RetainedEarningsAccumulatedLosses 2025-01-31 14628519 core:ShareCapitalOrdinaryShareClass1 2026-01-31 14628519 core:ShareCapitalOrdinaryShareClass1 2025-01-31 14628519 bus:Director2 2025-02-01 2026-01-31 14628519 core:IntangibleAssetsOtherThanGoodwill 2025-02-01 2026-01-31 14628519 core:PatentsTrademarksLicencesConcessionsSimilar 2025-02-01 2026-01-31 14628519 core:ComputerEquipment 2025-02-01 2026-01-31 14628519 2024-02-01 2025-01-31 14628519 core:UKTax 2025-02-01 2026-01-31 14628519 core:UKTax 2024-02-01 2025-01-31 14628519 core:PatentsTrademarksLicencesConcessionsSimilar 2025-01-31 14628519 core:PatentsTrademarksLicencesConcessionsSimilar core:ExternallyAcquiredIntangibleAssets 2025-02-01 2026-01-31 14628519 core:OtherPropertyPlantEquipment 2025-01-31 14628519 core:OtherPropertyPlantEquipment 2025-02-01 2026-01-31 14628519 bus:OrdinaryShareClass1 2025-02-01 2026-01-31 14628519 bus:OrdinaryShareClass1 2026-01-31 14628519 bus:OrdinaryShareClass1 2025-01-31 14628519 bus:PrivateLimitedCompanyLtd 2025-02-01 2026-01-31 14628519 bus:FRS102 2025-02-01 2026-01-31 14628519 bus:AuditExemptWithAccountantsReport 2025-02-01 2026-01-31 14628519 bus:Director1 2025-02-01 2026-01-31 14628519 bus:Director3 2025-02-01 2026-01-31 14628519 bus:SmallCompaniesRegimeForAccounts 2025-02-01 2026-01-31 14628519 bus:FullAccounts 2025-02-01 2026-01-31 xbrli:pure xbrli:shares iso4217:GBP